Premium
Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia
Author(s) -
Alten Julia,
Klapper Wolfram,
Leuschner Ivo,
Eckert Cornelia,
Beier Rita,
Vallo Elisabeth,
Krause Martin,
Claviez Alexander,
Vieth Simon,
Bleckmann Kirsten,
Möricke Anja,
Schrappe Martin,
Cario Gunnar
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25523
Subject(s) - medicine , minimal residual disease , fulminant , lymphoblastic leukemia , disease , hemophagocytic lymphohistiocytosis , leukemia , sarcoma , histiocytic sarcoma , histiocyte , oncology , immunology , pathology
Histiocytic sarcoma (HS) is a rare disease with poor prognosis which may develop subsequent to acute lymphoblastic leukemia (ALL). Here we report two children treated within the AIEOP‐BFM ALL 2009 trial: one patient succumbed to fulminant hemophagocytic lymphohistiocytosis triggered by HS during ALL maintenance therapy, the other patient had a smoldering course of HS for over 2 years, and subsequently died after allogeneic stem cell transplantation. In both cases, HS and ALL were clonally related and apparent return of minimal residual disease (MRD) was detected by qPCR in bone marrow. Thus, HS should be considered in ALL when MRD appears to persist or reappear. Pediatr Blood Cancer 2015;62:1656–1660. © 2015 Wiley Periodicals, Inc.